Monkeypox and drug repurposing: seven potential antivirals to combat the viral disease

Ryan Varghese; Pal Patel; Dileep Kumar; Rohit Sharma

doi:10.1515/reveh-2023-0001

Article

Monkeypox and drug repurposing: seven potential antivirals to combat the viral disease

Ryan Varghese , Pal Patel , Dileep Kumar and Rohit Sharma

Published/Copyright: February 22, 2023

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Reviews on Environmental Health Volume 39 Issue 4

Abstract

The growing concern about the monkeypox (Mpox) virus infection has garnered a lot of public attention. However, the treatment options available to combat the same is limited to tecovirimat. Additionally, in a possible incidence of resistance, hypersensitivity, or adverse drug reaction, it is imperative to devise and reinforce the second-line therapy. Thus, in this editorial, the authors suggest seven antiviral drugs that could potentially be repurposed to combat the viral illness.

Keywords: antivirals; brincidofovir; drug repurposing; monkey pox; mpox; orthopoxviruses; pharmaceuticals; tecovirimat

Corresponding authors: Rohit Sharma, Department of Rasa Shastra and Bhaishajya Kalpana , Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, Uttar Pradesh, India, E-mail: rohitsharma@bhu.ac; and Dileep Kumar, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Pune Maharashtra, 411038, India; Department of Entomology, University of California, Davis, CA, 95616, USA; and UC Davis Comprehensive Cancer Center, University of California, Davis, One Shields Ave, Davis, CA, 95616, USA, E-mail: dileep.0@gmail.com

Ryan Varghese and Pal Patel are equally contributing author.

Research funding: None declared.
Author contributions: Conceptualization, D.K. and R.S.; writing—original draft preparation, R.V. and P.P.; writing—review and editing, D.K., R.S.; supervision, project administration, R.S. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Not Applicable.
Ethical approval: Not Applicable.

References

1. Adler, H, Gould, S, Hine, P, Snell, LB, Wong, W, Houlihan, CF, et al.. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022;22:1153–62. https://doi.org/10.1016/s1473-3099(22)00228-6.Search in Google Scholar PubMed PubMed Central

2. Desai, AN, Thompson, GR, Neumeister, SM, Arutyunova, AM, Trigg, K, Cohen, SH. Compassionate use of tecovirimat for the treatment of monkeypox infection. JAMA 2022;328:1348. https://doi.org/10.1001/jama.2022.15336.Search in Google Scholar PubMed PubMed Central

3. Thornhill, JP, Barkati, S, Walmsley, S, Rockstroh, J, Antinori, A, Harrison, LB, et al.. Monkeypox virus infection in humans across 16 countries — april–june 2022. N Engl J Med 2022;387:679–91. https://doi.org/10.1056/nejmoa2207323.Search in Google Scholar PubMed

4. Guarner, J, del Rio, C, Malani, PN. Monkeypox in 2022—what clinicians need to know. JAMA 2022;328:139. https://doi.org/10.1001/jama.2022.10802.Search in Google Scholar PubMed

5. Kozlov, M. How does monkeypox spread? What scientists know. Nature 2022;608:655–6. https://doi.org/10.1038/d41586-022-02178-w.Search in Google Scholar PubMed

6. Branswell, H. With monkeypox spreading globally, many experts believe the virus can’t be contained. STAT health. Available from: https://www.statnews.com/2022/07/19/monkeypox-spread-many-experts-believe-the-virus-cant-be-contained/ [Accessed 07 Sep 2022].Search in Google Scholar

7. Jeyaraman, M, Selvaraj, P, Halesh, MB, Jeyaraman, N, Nallakumarasamy, A, Gupta, M, et al.. Monkeypox: an emerging global public health emergency. Life 2022;12:1590. https://doi.org/10.3390/life12101590.Search in Google Scholar PubMed PubMed Central

8. Abduljalil, JM, Elfiky, AA. Repurposing antiviral drugs against the human monkeypox virus DNA-dependent RNA polymerase; in silico perspective. J Infect 2022;85:702–69. https://doi.org/10.1016/j.jinf.2022.09.002.Search in Google Scholar PubMed PubMed Central

9. Sahoo, AK, Augusthian, PD, Muralitharan, I, Vivek-Ananth, RP, Kumar, K, Kumar, G, et al.. In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs. Mol Divers 2022;1–16. https://doi.org/10.1007/s11030-022-10550-1.Search in Google Scholar PubMed PubMed Central

10. Lam, HYI, Guan, JS, Mu, Y. Silico repurposed drugs against monkeypox virus. Molecules 2022;27:5277. https://doi.org/10.3390/molecules27165277.Search in Google Scholar PubMed PubMed Central

11. Miskovsky, P. Hypericin - a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr Drug Targets 2002;3. https://doi.org/10.2174/1389450023348091.Search in Google Scholar PubMed

12. Akash, S, Islam, MR, Rahman, MM, Hossain, MS, Azad, AK, Sharma, R. Investigation of the new inhibitors by modified derivatives of pinocembrin for the treatment of monkeypox and marburg virus with different computational approaches. Biointerface Res Appl Chem 2023;13:534.Search in Google Scholar

Received: 2023-01-04

Accepted: 2023-02-02

Published Online: 2023-02-22

Published in Print: 2024-12-17

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/reveh-2023-0001

Keywords for this article

antivirals; brincidofovir; drug repurposing; monkey pox; mpox; orthopoxviruses; pharmaceuticals; tecovirimat